Skip to main content

Table 5 Risk factor analysis for PE occurrence within 1 year after lung cancer diagnosis

From: Could venous thromboembolism and major bleeding be indicators of lung cancer mortality? A nationwide database study

  UnivariateMultivariate**
  sHR (95% CI)p-valuesHR (95% CI)p-value
Age<  55
55–650.82 (0.45–1.48)0.5030.88 (0.48–1.60)0.665
65–750.75 (0.40–1.37)0.3460.91 (0.49–1.70)0.774
≥ 750.72 (0.39–1.33)0.2941.08 (0.56–2.08)0.828
GenderMale
Female1.63 (1.08–2.47)0.0201.68 (1.11–2.54)0.014
Metastasis 3.46 (2.18–5.50)< 0.00012.51 (1.48–4.26)0.0006
VTE concomitant with cancer diagnosis* 3.33 (0.80–13.97)0.100  
Lung cancer surgery 0.78 (0.41–1.50)0.456  
Other surgery 1.64 (0.98–2.75)0.061  
Chemotherapy 3.97 (2.58–6.09)< 0.00013.13 (1.88–5.20)< 0.0001
Bevacizumab 1.39 (0.44–4.42)0.577  
Oral targeted therapy 2.38 (1.02–5.53)0.045  
Radiotherapy 2.10 (1.29–3.43)0.003  
Blood transfusion 1.53 (0.70–3.34)0.286  
Non-surgical hospitalization 1.74 (1.14–2.65)0.011  
  1. *Risk of recurrent VTE beyond 6 months after the first VTE
  2. **Multivariate analysis adjusted for age and gender